MicroRNA-205-5p is upregulated in myelodysplastic syndromes and induces cell proliferation via PTEN suppression
- Authors
- Jang, Sook Jin; Choi, In-Sun; Park, Geon; Moon, Dae-Soo; Choi, Ji-Seon; Nam, Myung-Hyun; Yoon, Soo-Young; Choi, Cheol Hee; Kang, Seong-Ho
- Issue Date
- 8월-2016
- Publisher
- PERGAMON-ELSEVIER SCIENCE LTD
- Keywords
- MDS; miR-205-5p; Upregulation; Diagnosis; Oncogenea
- Citation
- LEUKEMIA RESEARCH, v.47, pp.172 - 177
- Indexed
- SCIE
SCOPUS
- Journal Title
- LEUKEMIA RESEARCH
- Volume
- 47
- Start Page
- 172
- End Page
- 177
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/87982
- DOI
- 10.1016/j.leukres.2016.06.003
- ISSN
- 0145-2126
- Abstract
- Micro (mi)RNA dysregulation is implicated in the development of myelodysplastic syndrome (MDS). Chromosomal abnormalities on 1q are frequently detected in Korean patients with MDS; however, how these are related to disease development is unknown. The present study compared the expression profiles of miRNAs encoded by chromosome 1q between 65 MDS patients and 11 controls. We found that miR-205-5p levels were 12.5 fold higher in the former (P=0.001). miR-205-5p level was increased in 44.7% of patients when an arbitrary 2(-Delta Ct) cut-off value of 1.25 was used. miR-205-5p expression data were used to generate a receiver operating characteristic (ROC) curve for miR-205-5p, for which the area under the curve (AUC) was 0.825 (95% confidence interval: 0.710-0.941; P=0.001). Moreover, transfection with a miR-205-5p mimic induced cell proliferation by inhibiting the expression of the tumor suppressor protein phosphatase and tensin homolog (PTEN). Our findings suggest that miR-205-5p upregulation contributes to MDS by suppressing PTEN and that miR-205-5p thus acts as an oncogene in hematopoietic cells. (C) 2016 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.